Search Results

Researchers at the Crick have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics. 

To mark this year’s World TB Day, we spoke to Robert Wilkinson, head of the Crick’s Tuberculosis Laboratory, about his team’s work in Africa, understanding the links between SARS-CoV-2 and TB infections.

We asked people across the Crick to tell us about their bright spots of 2020 and their hopes for 2021.

At the Crick we want to share our passion for science. Our Public Engagement team tell us how they have adapted and found new ways to share our work and support local people during the coronavirus pandemic.

David Bauer joined us at the Crick to establish the RNA Virus Replication Laboratory and is currently working on identifying existing antiviral drugs that could be repurposed as treatments for COVID-19. Hear from David on his plans for his new group at the Crick, and how being in the building over the summer played a key role in setting up new collaborations.

The Crick has published its 2020 statistics on animal research, showing a drop in the total number of animal research procedures carried out throughout the year due to COVID-19 disruptions.

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus.

Researchers at the Crick have found that a protein which is initially helpful in the body’s immune response to a virus, can later interfere with the repair of lung tissue. 

Enzo and Mike are Crick postdocs working to get a new faster, cheaper and simpler coronavirus testing method up and running.